Unfortunately, 20%–30% of haemophilia A patients develop inhibitory antibodies (‘inhibitors’) against FVIII that severely complicate treatment and increase morbidity and mortality risk (Lai and Lillicrap, 2017). Here, F8 is linked to hemophilia A.